COMP <GO>
RPRX vs ONC // EV/EBITDA & P/E VALUATION
Royalty Pharma plc (Class A) (NASDAQ) VS. BeOne Medicines Ltd. (NASDAQ) • 15-METRIC TALLY: RPRX 6
— ONC 6
▲ EV/EBITDA & P/E VALUATION LEADER: RPRX
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
valuation
27.8x
LAST: $370.33 (-0.33%) • MKT CAP: $42.25B
valuation
63.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. ONC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | ONC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 87.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 10.50% | -3.50 | ONC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 27.8x | 63.9x | -36.10 | RPRX | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 2.23% | +4.06 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 8.40% | +57.20 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 5.40% | +27.00 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 40.20% | -35.10 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 6.68 | -3.78 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 53.6 | +15.00 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.98 | -0.04 | ONC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 123.6x | -77.80 | RPRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.91B | $42.25B | -$4.34B | ONC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | ONC REV | RPRX GROSS % | ONC GROSS % | RPRX FCF | ONC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $5.34B | — | 87.5% | $2.38B | $941.7M |
| FY 2024 | $2.26B | $3.81B | — | 84.4% | $2.67B | -$633.3M |
| FY 2023 | $2.35B | $2.46B | — | — | $2.88B | -$1.27B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
ONC // BETA 0.98